Towa Pharmaceutical Co Ltd (4553:TSE) Stock Forecast
Alert
Its only available to paid users.
N/A
Based on the Towa Pharmaceutical Co Ltd stock forecast from 0 analysts, the average analyst target price for Towa Pharmaceutical Co Ltd is not available over the next 12 months. Towa Pharmaceutical Co Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Towa Pharmaceutical Co Ltd is Slightly Bullish , which is based on 8 positive signals and 6 negative signals. At the last closing, Towa Pharmaceutical Co Ltd’s stock price was JPY 2,915.00. Towa Pharmaceutical Co Ltd’s stock price has changed by +4.56% over the past week, +3.11% over the past month and +25.11% over the last year.
No recent analyst target price found for Towa Pharmaceutical Co Ltd
No recent average analyst rating found for Towa Pharmaceutical Co Ltd
Company Overview Towa Pharmaceutical Co Ltd
Towa Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells ethical drugs, active pharmaceutical ingredients, and intermediates in Japan. The company provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products. It also offers IT service related to healthcare; and disease risk testing services. In addition, the company is involved with research and development of diagnostic drugs; and planning, development and OEM manufacturing of health food, pharmaceuticals, general food and other products. The company was founded in 1951 and is headquartered in Osaka, Japan. Read Less
Towa Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells ethical drugs, active pharmaceutical ingredients, and intermediates in Japan. The company provides its products in the therapeutic areas of digestive system, nervous system, a...Read More
Frequently Asked Questions About Towa Pharmaceutical Co Ltd (4553:TSE) Stock
Stock Target Advisor's fundamental analysis for Towa Pharmaceutical Co Ltd's stock is Slightly Bullish .
4553:TSE stock's dividend yield is 2.07%.
Our analysis grades 4553:TSE stock's dividend yield at F. This means that 4553:TSE stock's dividend yield is above 13% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the TSE exchange.
Based on this 4553:TSE may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on 4553:TSE's stock to indicate what its average analyst target is.
4553:TSE stock's Price/Earning ratio is 8.80.
Our analysis grades 4553:TSE stock's Price / Earning ratio at B. This means that 4553:TSE stock's Price/Earning ratio is above 15% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the TSE exchange.
Based on this 4553:TSE may be undervalued for its sector.
The last closing price of 4553:TSE's stock was JPY 2,915.00.
The most recent market capitalization for 4553:TSE is JPY 138.77B.
Unfortunately we do not have enough analyst data on 4553:TSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Towa Pharmaceutical Co Ltd's stock.
As per our most recent records Towa Pharmaceutical Co Ltd has 4,588 Employees.
Towa Pharmaceutical Co Ltd's registered address is 2-11, Shinbashi-cho, Osaka, Japan, 571-8580.
You can get more information about it from Towa Pharmaceutical Co Ltd's website at https://www.towayakuhin.co.jp.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior Dividend Growth
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
High dividend returns
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Towa Pharmaceutical Co Ltd (4553:TSE) Stock
Stock Target Advisor's fundamental analysis for Towa Pharmaceutical Co Ltd's stock is Slightly Bullish .
4553:TSE stock's dividend yield is 2.07%.
Our analysis grades 4553:TSE stock's dividend yield at F. This means that 4553:TSE stock's dividend yield is above 13% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the TSE exchange.
Based on this 4553:TSE may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on 4553:TSE's stock to indicate what its average analyst target is.
4553:TSE stock's Price/Earning ratio is 8.80.
Our analysis grades 4553:TSE stock's Price / Earning ratio at B. This means that 4553:TSE stock's Price/Earning ratio is above 15% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the TSE exchange.
Based on this 4553:TSE may be undervalued for its sector.
The last closing price of 4553:TSE's stock was JPY 2,915.00.
The most recent market capitalization for 4553:TSE is JPY 138.77B.
Unfortunately we do not have enough analyst data on 4553:TSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Towa Pharmaceutical Co Ltd's stock.
As per our most recent records Towa Pharmaceutical Co Ltd has 4,588 Employees.
Towa Pharmaceutical Co Ltd's registered address is 2-11, Shinbashi-cho, Osaka, Japan, 571-8580.
You can get more information about it from Towa Pharmaceutical Co Ltd's website at https://www.towayakuhin.co.jp.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 4553:TSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
